Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12345678910111213...4748»
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Co-Inhibition of MEK/RTK Pathways Induces High Therapeutic Efficacy in Pan-KRAS-Mutant Non-Small Cell Lung Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1481;    
    Additionally, plasma protein profiling analysis indicated upregulation of multiple protein levels in blood, such as PLP2 and GINS1, potentially associated with drug response. Conclusions : Collectively, this study provides a potential combinational therapeutic strategy for pan-KRAS-mutant NSCLC through co-targeting MEK and RTKs.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Efficacy and Safety of Tislelizumab Plus Anlotinib and 2-Cycle Irinotecan as Second-Line Treatment for ES-Small Cell Lung Cancer(ESTAIL) (20D) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1090;    
    P=N/A
    Conclusions : Tislelizumab combined with Anlotinib and 2-cycle Irinotecan as second-line Treatment for ES-SCLC demonstrated promising efficacy and safety, especially pts who failed to first-line treatment of PD-L1 inhibitor +EP/EC could benefit from it. The key subgroup analysis of ORR Response Total (N=32) brain metastases ( yes) brain metastases(No) First-line treatment(EP/EC) First-line treatment(PD-L1+EP/EC) Time of First line platinum to relapse(>3months) Time of First line platinum to relapse(<3months) BoR,n (%) PR 16 9 7 13 3 5 8 SD 12 5 7 7 5 1 6 PD 1 0 1 0 1 0 0 NE 3 1 2 3 0 1 2 ORR,n(%) 16(50) 9(60) 7(41.2) 13(56.5) 3(33.3) 5(71.4) 8(50) DCR,n(%) 28(87.5) 14(93) 14(82) 20(87) 8(88.9) 6(85.7) 14(87.5)
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Retrospective data, Journal:  Safety and Efficiency of Anlotinib in Patients with Recurrent Grade 4 Glioma: A Single-Center Retrospective Analysis. (Pubmed Central) -  Jul 23, 2024   
    Conclusions : Camrelizumab plus apatinib combined with chemotherapy showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a potential treatment option in patients with resectable stage III NSCLC. For recurrent grade 4 glioma, anlotinib can be considered as a supplement to the standard STUPP treatment, especially for the patient with anlotinib target genes.
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Focus V (anlotinib) / Advenchen, Sino Biopharm, tiragolumab (RG6058) / Roche
    Clinical, Review, Journal:  The efficacy and safety of immunotherapy as first-line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data. (Pubmed Central) -  Jul 19, 2024   
    The incidence of ?grade 3 treatment-emergent adverse events (TEAEs) was significantly higher in the PD-1 group compared to the PD-L1 group (85.4% vs. 69.6%, P <.001), whereas the incidence of irAEs was similar between the two groups. This reconstructed IPD analysis revealed that PD-1 inhibitors plus chemotherapy achieved similar efficacy to PD-L1 inhibitors plus chemotherapy as first-line treatment in ES-SCLC patients, whereas PD-L1 inhibitors plus chemotherapy had a better safety profile.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date:  Anlotinib Capsules in the Treatment for IPF/PF-ILDs (clinicaltrials.gov) -  Jul 17, 2024   
    P2/3,  N=30, Recruiting, 
    Trial primary completion date: Apr 2023 --> Dec 2023 Trial completion date: Jul 2024 --> Jul 2025
  • ||||||||||  NHWD-870 / Ningbo Wenda Pharma, Opdivo (nivolumab) / BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Primary thyroid nuclear protein in testis carcinoma: a case report and literature review. (Pubmed Central) -  Jul 17, 2024   
    Gene rearrangement detection is also helpful for diagnosis and treatment. At present, surgery and radiation are still first choices for NC, and advances in targeted immunotherapy such as bromodomain and end motif inhibitors (BETi) may bring better treatment options to patients.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib induces neuronal-like differentiation of neuroblastoma by downregulating CRMP5. (Pubmed Central) -  Jul 9, 2024   
    These findings highlight the potential of anlotinib as an anti-neuroblastoma agent. It may suppress tumor proliferation and invasion by promoting the differentiation of tumor cells towards a neuronal-like state, and this differentiation therapy effect involves the inhibition of CRMP5 signaling.
  • ||||||||||  Pinorubin (pirarubicin) / Sanofi, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal:  Myxoinflammatory fibroblastic sarcoma of the liver: Case report and literature review. (Pubmed Central) -  Jul 5, 2024   
    Surgical resection remains the primary treatment option for MIFS in the absence of any contraindications. Because the recurrence rate of MIFS is high, meticulous long-term monitoring is required.
  • ||||||||||  Review, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review. (Pubmed Central) -  Jul 5, 2024   
    The current evidence showed that ICIs, including atezolizumab plus bevacizumab, sintilimab plus bevacizumab/bevacizumab biosimilar, nivolumab, camrelizumab plus rivoceranib, pembrolizumab plus lenvatinib, tislelizumab, durvalumab, and cabozantinib plus atezolizumab, are probably not cost-effective in comparison with tyrosine kinase inhibitors or other ICIs...Our review demonstrated that ICIs were not a cost-effective intervention in advanced HCC. Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Desmoplastic small round cell tumor of the kidney: a case report and discussion. (Pubmed Central) -  Jul 5, 2024   
    An abdominal CT scan conducted 11 months after second-stage surgery did not reveal any recurrence of abdominal tumors; however bone metastases persisted. The patient is currently receiving oral targeted therapy with anlotinib while ongoing follow-up continues.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Apatinib manifests an unexpectedly favorable outcome in the management of axillary lymph node follicular dendritic cell sarcoma: a case report. (Pubmed Central) -  Jul 4, 2024   
    A one-cycle trial of albumin-bound paclitaxel yielded unsatisfactory results...Due to the patient's limited financial circumstances, we, in the absence of guideline recommendations and evidence from evidence-based medicine, achieved a 10-month progression-free survival (PFS) solely based on experiential use of the anti-angiogenic drug, Apatinib. The purpose of this case report is to provide additional therapeutic options for FDCS treatment and to pave the way for exploring the mechanism of action of Apatinib in FDCS.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry. (Pubmed Central) -  Jul 3, 2024   
    Notably, the downregulation of VEGFR-2, FGFR-1, PDGFR-?, and PI3K underscored the multitargeted antitumor activity of anlotinib. Our findings emphasize the therapeutic potential of anlotinib in targeting angiogenesis and vasculogenic mimicry, contributing to the development of novel strategies for combating malignant melanoma.